The Global Health Impact
Manufacturers’ Index.
Evaluating how generic pharmaceutical companies’ drugs impact the health of populations devastated by disease. Manufacturers are ranked by DALYs (Disability Adjusted Life Years) addressed and their relative cost-effectiveness.
Company scores are calculated based on the DALYs alleviated by their generic products. This model takes into consideration the global need for essential medicines, the drugs’ effectiveness, and the cost-effectiveness of generic distribution in reaching underserved populations.
Proportion of Global Disease Burden Alleviated by Manufacturer Company’s Drugs — Malaria
Comparative Global Health Impact of Manufacturers
Limitations
The rankings on this website are meant to provide a metric of the impacts of generic manufacturers’ drugs on a few important global diseases. This index is not meant to measure how “good” a company is in relation to its peers, or how effective it has been at ensuring access to its drugs. The impacts of the ranked companies’ drugs is only one of many measures of a company’s overall fulfillment of its social responsibilities.
For instance, companies with high scores on this index may still have infrastructure challenges in certain regions. These rankings are best read in combination with other academic and civil society analyses of the generic drug market.
“For a view focused on originator drugs and the impact of patent-holding pharmaceutical companies, see the patent holders’ tab.”